<![CDATA[BiolineRX News]]> http://www.biolinerx.com/RSS.asp he 16/09/2011 720 <![CDATA[BioLineRx Announces Publication of Pre-clinical Results Demonstrating Efficacy of BL-7010, an Oral Treatment for Celiac Disease and Gluten Sensitivity ]]> http://www.biolinerx.com/default.asp?PageID=16&ItemID=109 Gastroenterology]]> 21/02/2012 http://www.biolinerx.com/default.asp?PageID=16&ItemID=109 <![CDATA[BioLineRx to place $15 million in securities with Institutional Investors]]> http://www.biolinerx.com/default.asp?PageID=16&ItemID=108 16/02/2012 http://www.biolinerx.com/default.asp?PageID=16&ItemID=108 <![CDATA[BioLineRx Presenting at BIO CEO & Investor Conference in New York on February 14th]]> http://www.biolinerx.com/default.asp?PageID=63&ItemID=107 06/02/2012 http://www.biolinerx.com/default.asp?PageID=63&ItemID=107 <![CDATA[BioLineRx In-Licenses Second Oral Hepatitis C Treatment ]]> http://www.biolinerx.com/default.asp?PageID=16&ItemID=106 Worldwide, exclusive deal signed with Genoscience and RFS Pharma for development and commercialization of BL-8030

Advantages of BL-8030 include high specificity, improved resistance profile, reduced toxicity and potentially reduced drug-drug interactions

]]> 06/02/2012 http://www.biolinerx.com/default.asp?PageID=16&ItemID=106 <![CDATA[BioLine Signed Agreement for Drug Development and Share Price Soared]]> http://www.biolinerx.com/default.asp?PageID=17&ItemID=105 26/01/2012 http://www.biolinerx.com/default.asp?PageID=17&ItemID=105 <![CDATA[BioLineRx Signs Exclusive License Agreement for BL-8020, an Oral Treatment for Hepatitis C ]]> http://www.biolinerx.com/default.asp?PageID=16&ItemID=104 24/01/2012 http://www.biolinerx.com/default.asp?PageID=16&ItemID=104 <![CDATA[BioLineRx Announces Initiation of CE Mark Registration Trial for BCM (BL-1040), a Novel Medical Device for Prevention of Cardiac Remodeling Following Acute Myocardial Infarction ]]> http://www.biolinerx.com/default.asp?PageID=16&ItemID=102 03/01/2012 http://www.biolinerx.com/default.asp?PageID=16&ItemID=102 <![CDATA[BioLineRx to Develop and Commercialize Novel Peptide Drug Candidates Discovered by Compugen ]]> http://www.biolinerx.com/default.asp?PageID=16&ItemID=101 13/12/2011 http://www.biolinerx.com/default.asp?PageID=16&ItemID=101 <![CDATA[Positive Results for BioLine's Treatment for Neuropathic Pain]]> http://www.biolinerx.com/default.asp?PageID=17&ItemID=103 07/12/2011 http://www.biolinerx.com/default.asp?PageID=17&ItemID=103 <![CDATA[BioLineRx Announces Positive Final Results from Phase Ia Clinical Trial of BL-1021 for Neuropathic Pain]]> http://www.biolinerx.com/default.asp?PageID=16&ItemID=99 - BL-1021 was shown to be safe and well tolerated -
- Safety is a significant concern in current neuropathic pain treatments -

]]> 06/12/2011 http://www.biolinerx.com/default.asp?PageID=16&ItemID=99 <![CDATA[BioLineRx Reports Third Quarter 2011 Financial Results]]> http://www.biolinerx.com/default.asp?PageID=16&ItemID=98 29/11/2011 http://www.biolinerx.com/default.asp?PageID=16&ItemID=98 <![CDATA[ Philip Serlin, BioLineRx CFOO, on Bloomberg TV]]> http://www.biolinerx.com/default.asp?PageID=17&ItemID=97 28/11/2011 http://www.biolinerx.com/default.asp?PageID=17&ItemID=97 <![CDATA[BioLineRx Announces Receipt of Approval in India to Commence Phase II/III CLARITY Clinical Trial of BL-1020 for Treatment of Schizophrenia ]]> http://www.biolinerx.com/default.asp?PageID=16&ItemID=96 22/11/2011 http://www.biolinerx.com/default.asp?PageID=16&ItemID=96 <![CDATA[Moving Remedies from Lab to Pharmacy]]> http://www.biolinerx.com/default.asp?PageID=17&ItemID=95 01/11/2011 http://www.biolinerx.com/default.asp?PageID=17&ItemID=95 <![CDATA[Meet us at Bio-Europe 2011 ]]> http://www.biolinerx.com/default.asp?PageID=63&ItemID=94 26/10/2011 http://www.biolinerx.com/default.asp?PageID=63&ItemID=94 <![CDATA[BioLineRx to Present Data from the Successfully Completed Phase IIb trial of BL-1020 at European Conference on Schizophrenia Research ]]> http://www.biolinerx.com/default.asp?PageID=16&ItemID=91 27/09/2011 http://www.biolinerx.com/default.asp?PageID=16&ItemID=91 <![CDATA[BioLineRx to Present Data from the Successfully Completed Phase IIb trial of BL-1020 at European Conference on Schizophrenia Research ]]> http://www.biolinerx.com/default.asp?PageID=63&ItemID=92  

]]> 23/09/2011 http://www.biolinerx.com/default.asp?PageID=63&ItemID=92 <![CDATA[BioLineRx Presents Preliminary Results of Phase Ia Clinical Trial on BL-1021, a New Chemical Entity for Treatment of Neuropathic Pain, at Pain Therapeutics Summit]]> http://www.biolinerx.com/default.asp?PageID=63&ItemID=93 20/09/2011 http://www.biolinerx.com/default.asp?PageID=63&ItemID=93 <![CDATA[BioLineRx to Present at Annual UBS Global Life Sciences Conference in New York on September 21st]]> http://www.biolinerx.com/default.asp?PageID=16&ItemID=90  

]]> 16/09/2011 http://www.biolinerx.com/default.asp?PageID=16&ItemID=90 <![CDATA[BioLineRx Presenting at Annual UBS Global Life Sciences Conference in New York on September 21st]]> http://www.biolinerx.com/default.asp?PageID=63&ItemID=89

]]> 16/09/2011 http://www.biolinerx.com/default.asp?PageID=63&ItemID=89